Vendor, Morristown, NJ, part of Orexo Ab
Orexo US Inc.
UEI MN1MPMBCVVD5, CAGE 6Y7L3
2 awards and $11,450,712 obligated between May 27, 2025 and September 4, 2026, 100% under full and open competition, against 666.3 offers on average where reported. 3 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $11,450,712 |
| Department of Veterans Affairs | $0 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $11,450,712 |
| Pharmaceutical Preparation ManufacturingNAICS 325412 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50125C00010Definitive Contract, September 24, 2025, Full and Open Competition, 1 offersSolicitation | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Clinical Development of OX390 (Atipamezole) as an ?2 Agonist Reversal Agent for Human Use to Counteract the Sedative Effects of Xylazine, MeNAICS 541714, PSC AN13 | $11,450,712 |
| 36F79722D0163January 29, 2024, Full and Open Competition, 999 offers | Nac Federal Supply ScheduleDepartment of Veterans Affairs | CancellationNAICS 334510, PSC 6515 | $0 |
| V797D60656November 22, 2024, Full and Open Competition, 999 offers | Nac Federal Supply ScheduleDepartment of Veterans Affairs | 2025 Public Law Pricing UpdateNAICS 325412, PSC 6505 | $0 |
- Places of performance
- New Jersey
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental Development6505 Drugs and Biologicals
- Transactions
- 8 across 2 awards